Written by: Li Enci
Last update date: 2021-03-19 17:08
There have been 96 cases of N501Y variant virus in Hong Kong so far (19th).
Liu Yulong, chairman of the Scientific Committee on Vaccine-Preventable Diseases, stated yesterday (18th) that the Fubitai vaccine is effective against mutant viruses in the United Kingdom and Brazil, and “relatively effective against the mutant viruses in South Africa.” AstraZeneca vaccine is also effective against the British and Brazilian variants. The virus is effective, but it is not effective against the South African virus.
Cui Junming, president of the Hong Kong Institute of Hospital Pharmacists, explained that both Fubital and AstraZeneca vaccines attack the spike protein of the virus, while the shape of the spike protein of the South African variant virus strain has become different, and the antibody cannot be identified, which reduces the ability to neutralize.
▼Full list of 29 vaccination centers on Hong Kong Island, Kowloon, New Territories and Outlying Islands▼
Zhang Zhujun, Director of the Department of Infectious Diseases of the Center for Health Protection of the Department of Health, said that a total of 96 cases of the N501Y variant virus have been recorded in Hong Kong, all of which are imported cases. Among them, 37 were British variants, 5 were Brazilian variants, 8 were South African variants, and 46 were cases. uncategorized.
Liu Yulong pointed out that the protection rate of Fubitai vaccine is effective against the mutant virus, but Kexing vaccine has no data to support it.
(Photo by Li Zetong)
Liu Yulong, chairman of the Scientific Committee on Vaccine Preventable Diseases, said that the virus variants will affect the effectiveness of the vaccine and cause the virus to escape.
The committee found from the data literature that the Fubitai vaccine is effective against the mutant virus in the United Kingdom and Brazil, but is "relatively ineffective" against the mutant virus in South Africa.
However, Kexing vaccine has no data showing whether it is effective against variant virus strains.
As for the AstraZeneca vaccine to be supplied to Hong Kong, it is also effective against the variant viruses in the United Kingdom and Brazil, but not against the variant viruses in South Africa.
▼See the details of the scheduled vaccination and side effects of Kexing and BioNTech in the 3 pictures▼
According to WHO data, the infectivity of the three variants of the virus has increased; after the patient is infected with the British variant, the risk of hospitalization, serious illness and death is higher; while the South African variant has poor neutralization ability, that is, the second infection of people who have been infected with new coronary pneumonia. Increased risk of infection.
Lin Weixun, a specialist in the Department of Infection and Infectious Diseases, said that the location and number of mutations in various variant virus strains are different. If the shape of the viral spike protein (S protein) changes, the antibody may not be "fit", and the neutralizing ability will be reduced. decline.
Cui Junming, president of the Hong Kong Society of Hospital Pharmacists, explained that both Fubital and AstraZeneca vaccines attack the spike protein of the virus, while the shape of the spike protein of the South African variant virus strain has become different. The shape of the (spike protein) matches. If you don’t agree, you don’t recognize it.” He also said that at present, only Johnson & Johnson vaccine has been proven effective against the South African variant virus strain, but the Hong Kong government has not purchased it.
▼On March 10, the first day of Fubitai vaccine, the situation of the vaccination center in the Zhongshan Memorial Park Gym▼
Vaccines｜Fobitai can respond to the variant virus Lin Wenjian: More than half of the vaccination rate can relax epidemic prevention measures
New crown pneumonia | Nigerian variant virus found in Guangdong may cause secondary infection in recovered patients
New Coronary Pneumonia｜The Philippines records the first confirmed case of a highly infectious Brazilian variant virus
New crown vaccine | Xu Shuchang: Vaccine passport may not be feasible due to variant virus can reduce vaccine efficacy
New Coronary Pneumonia｜British study: The fatality rate of the variant virus B.1.1.7 is significantly higher
New crown pneumonia new crown vaccine China Kexing BioNTech/Fosun vaccine Fubitai vaccine AstraZeneca vaccine